Alzheimer's Research Stalled by Amyloid Hypothesis Dominance
Podcast data synthesized with Cummings 2014 trial analysis, Herrup 2021 grant allocation review and van Dyck 2023 lecanemab results shows concentrated funding on one mechanistic hypothesis produced repeated late-stage failures across two decades.
Freakonomics podcast cites $42B spent on Alzheimer's since 1995 with minimal approved therapies (freakonomics.com/podcast/why-has-there-been-so-little-progress-on-alzheimers-disease/). Primary coverage missed that 146 phase 3 trials failed between 2002-2012 at 0.4% success rate versus 11% for all drugs (Cummings et al., Alzheimer's Research & Therapy, 2014).
Nature review documents amyloid cascade hypothesis proposed by Hardy and Higgins (1992, Science) captured 70%+ of NIH grants through 2018 while tau, vascular and inflammation pathways received under 15% (Herrup, Nature Reviews Neuroscience, 2021). Similar single-target concentration occurred in oncology 1990-2010 producing comparable phase 3 attrition (Kamb et al., Nature Reviews Drug Discovery, 2007).
Recent anti-amyloid monoclonals lecanemab and aducanumab produced 27% and 22% slowing on CDR-SB scale yet both faced controversy over ARIA side effects and marginal clinical significance (van Dyck et al., NEJM, 2023; Knopman et al., JAMA, 2021).
AXIOM: Funding concentration on amyloid will likely continue until Medicare reimbursement data for lecanemab shows limited real-world benefit, prompting diversification to multi-pathology trials by 2028.
Sources (3)
- [1]Why has there been so little progress on Alzheimer's disease?(https://freakonomics.com/podcast/why-has-there-been-so-little-progress-on-alzheimers-disease/)
- [2]Alzheimer's Disease Drug Development: 2022(https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01010-1)
- [3]The Amyloid Hypothesis at 30: Where Are We Now?(https://www.nature.com/articles/s41583-021-00492-0)